Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure

Pieter F van den Berg; Joseph Pierre Aboumsallem; Elles M Screever; Canxia Shi; Sanne de Wit; Valentina Bracun; Laura I Yousif; Lotte Geerlings; Dongyu Wang; Jennifer E Ho; Stephan J L Bakker; Bert van der Vegt; Herman H W Silljé; Rudolf A de Boer; Wouter C Meijers

doi:10.1016/j.jaccao.2023.03.015

Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure

Pieter F van den Berg, Joseph Pierre Aboumsallem, Elles M Screever, Canxia Shi, Sanne de Wit, Valentina Bracun, Laura I Yousif, Lotte Geerlings, Dongyu Wang, Jennifer E Ho, Stephan J L Bakker, Bert van der Vegt, Herman H W Silljé, Rudolf A de Boer, Wouter C Meijers^*

^*Corresponding author voor dit werk

Onderzoeksoutput: Article › Academic › peer review

8 Citaten (Scopus)

71 Downloads (Pure)

Samenvatting

BACKGROUND: Cancer and heart failure (HF) are the leading causes of death in the Western world. Shared mechanisms such as fibrosis may underlie either disease entity, furthermore it is unknown whether this relationship is sex-specific.

OBJECTIVES: We sought to investigate how fibrosis-related biomarker galectin-3 (gal-3) aids in identifying individuals at risk for new-onset cancer and HF, and how this differs between sexes.

METHODS: Gal-3 was measured at baseline and at 4-year follow-up in 5,786 patients of the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. The total follow-up period was 11.5 years. An increase of ≥50% in gal-3 levels between measurements was considered relevant. We performed sex-stratified log-rank tests and Cox regression analyses overall and by sex to evaluate the association of gal-3 over time with both new-onset cancer and new-onset HF.

RESULTS: Of the 5,786 healthy participants (50% males), 399 (59% males) developed new-onset cancer, and 192 (65% males) developed new-onset HF. In males, an increase in gal-3 was significantly associated with new-onset cancer (both combined and certain cancer-specific subtypes), after adjusting for age, body mass index, hypertension, smoking status, estimated glomerular filtration rate, diabetes mellitus, triglycerides, coronary artery disease, and C-reactive protein (HR: 1.89; 95% CI: 1.32-2.71; P < 0.001). Similar analyses demonstrated an association with new-onset HF in males (HR: 1.77; 95% CI: 1.07-2.95; P = 0.028). In females, changes in gal-3 over time were neither associated with new-onset cancer nor new-onset HF.

CONCLUSIONS: Gal-3, a marker of fibrosis, is associated with new-onset cancer and new-onset HF in males, but not in females.

Originele taal-2	English
Pagina's (van-tot)	445-453
Aantal pagina's	9
Tijdschrift	Jacc: cardiooncology
Volume	5
Nummer van het tijdschrift	4
DOI's	https://doi.org/10.1016/j.jaccao.2023.03.015
Status	Published - aug.-2023

Toegang tot document

10.1016/j.jaccao.2023.03.015Licentie: CC BY-NC-ND

Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart FailureFinal publisher's version, 956 KBLicentie: CC BY-NC-ND

Handle.net

Permanente koppeling

Citeer dit

van den Berg, P. F., Aboumsallem, J. P., Screever, E. M., Shi, C., de Wit, S., Bracun, V., Yousif, L. I., Geerlings, L., Wang, D., Ho, J. E., Bakker, S. J. L., van der Vegt, B., Silljé, H. H. W., de Boer, R. A., & Meijers, W. C. (2023). Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure. Jacc: cardiooncology, 5(4), 445-453. https://doi.org/10.1016/j.jaccao.2023.03.015

@article{0ca1bbf58270419e989d09f956473fcb,

title = "Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure",

abstract = "BACKGROUND: Cancer and heart failure (HF) are the leading causes of death in the Western world. Shared mechanisms such as fibrosis may underlie either disease entity, furthermore it is unknown whether this relationship is sex-specific.OBJECTIVES: We sought to investigate how fibrosis-related biomarker galectin-3 (gal-3) aids in identifying individuals at risk for new-onset cancer and HF, and how this differs between sexes.METHODS: Gal-3 was measured at baseline and at 4-year follow-up in 5,786 patients of the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. The total follow-up period was 11.5 years. An increase of ≥50% in gal-3 levels between measurements was considered relevant. We performed sex-stratified log-rank tests and Cox regression analyses overall and by sex to evaluate the association of gal-3 over time with both new-onset cancer and new-onset HF.RESULTS: Of the 5,786 healthy participants (50% males), 399 (59% males) developed new-onset cancer, and 192 (65% males) developed new-onset HF. In males, an increase in gal-3 was significantly associated with new-onset cancer (both combined and certain cancer-specific subtypes), after adjusting for age, body mass index, hypertension, smoking status, estimated glomerular filtration rate, diabetes mellitus, triglycerides, coronary artery disease, and C-reactive protein (HR: 1.89; 95% CI: 1.32-2.71; P < 0.001). Similar analyses demonstrated an association with new-onset HF in males (HR: 1.77; 95% CI: 1.07-2.95; P = 0.028). In females, changes in gal-3 over time were neither associated with new-onset cancer nor new-onset HF. CONCLUSIONS: Gal-3, a marker of fibrosis, is associated with new-onset cancer and new-onset HF in males, but not in females.",

author = "{van den Berg}, {Pieter F} and Aboumsallem, {Joseph Pierre} and Screever, {Elles M} and Canxia Shi and {de Wit}, Sanne and Valentina Bracun and Yousif, {Laura I} and Lotte Geerlings and Dongyu Wang and Ho, {Jennifer E} and Bakker, {Stephan J L} and {van der Vegt}, Bert and Sillj{\'e}, {Herman H W} and {de Boer}, {Rudolf A} and Meijers, {Wouter C}",

note = "{\textcopyright} 2023 The Authors.",

year = "2023",

month = aug,

doi = "10.1016/j.jaccao.2023.03.015",

language = "English",

volume = "5",

pages = "445--453",

journal = "Jacc: cardiooncology",

issn = "2666-0873",

publisher = "Elsevier",

number = "4",

}

van den Berg, PF, Aboumsallem, JP, Screever, EM , Shi, C, de Wit, S, Bracun, V, Yousif, LI, Geerlings, L, Wang, D, Ho, JE, Bakker, SJL , van der Vegt, B , Silljé, HHW , de Boer, RA & Meijers, WC 2023, 'Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure', Jacc: cardiooncology, vol. 5, nr. 4, blz. 445-453. https://doi.org/10.1016/j.jaccao.2023.03.015

TY - JOUR

T1 - Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure

AU - van den Berg, Pieter F

AU - Aboumsallem, Joseph Pierre

AU - Screever, Elles M

AU - Shi, Canxia

AU - de Wit, Sanne

AU - Bracun, Valentina

AU - Yousif, Laura I

AU - Geerlings, Lotte

AU - Wang, Dongyu

AU - Ho, Jennifer E

AU - Bakker, Stephan J L

AU - van der Vegt, Bert

AU - Silljé, Herman H W

AU - de Boer, Rudolf A

AU - Meijers, Wouter C

PY - 2023/8

Y1 - 2023/8

N2 - BACKGROUND: Cancer and heart failure (HF) are the leading causes of death in the Western world. Shared mechanisms such as fibrosis may underlie either disease entity, furthermore it is unknown whether this relationship is sex-specific.OBJECTIVES: We sought to investigate how fibrosis-related biomarker galectin-3 (gal-3) aids in identifying individuals at risk for new-onset cancer and HF, and how this differs between sexes.METHODS: Gal-3 was measured at baseline and at 4-year follow-up in 5,786 patients of the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. The total follow-up period was 11.5 years. An increase of ≥50% in gal-3 levels between measurements was considered relevant. We performed sex-stratified log-rank tests and Cox regression analyses overall and by sex to evaluate the association of gal-3 over time with both new-onset cancer and new-onset HF.RESULTS: Of the 5,786 healthy participants (50% males), 399 (59% males) developed new-onset cancer, and 192 (65% males) developed new-onset HF. In males, an increase in gal-3 was significantly associated with new-onset cancer (both combined and certain cancer-specific subtypes), after adjusting for age, body mass index, hypertension, smoking status, estimated glomerular filtration rate, diabetes mellitus, triglycerides, coronary artery disease, and C-reactive protein (HR: 1.89; 95% CI: 1.32-2.71; P < 0.001). Similar analyses demonstrated an association with new-onset HF in males (HR: 1.77; 95% CI: 1.07-2.95; P = 0.028). In females, changes in gal-3 over time were neither associated with new-onset cancer nor new-onset HF. CONCLUSIONS: Gal-3, a marker of fibrosis, is associated with new-onset cancer and new-onset HF in males, but not in females.

AB - BACKGROUND: Cancer and heart failure (HF) are the leading causes of death in the Western world. Shared mechanisms such as fibrosis may underlie either disease entity, furthermore it is unknown whether this relationship is sex-specific.OBJECTIVES: We sought to investigate how fibrosis-related biomarker galectin-3 (gal-3) aids in identifying individuals at risk for new-onset cancer and HF, and how this differs between sexes.METHODS: Gal-3 was measured at baseline and at 4-year follow-up in 5,786 patients of the PREVEND (Prevention of Renal and Vascular Endstage Disease) study. The total follow-up period was 11.5 years. An increase of ≥50% in gal-3 levels between measurements was considered relevant. We performed sex-stratified log-rank tests and Cox regression analyses overall and by sex to evaluate the association of gal-3 over time with both new-onset cancer and new-onset HF.RESULTS: Of the 5,786 healthy participants (50% males), 399 (59% males) developed new-onset cancer, and 192 (65% males) developed new-onset HF. In males, an increase in gal-3 was significantly associated with new-onset cancer (both combined and certain cancer-specific subtypes), after adjusting for age, body mass index, hypertension, smoking status, estimated glomerular filtration rate, diabetes mellitus, triglycerides, coronary artery disease, and C-reactive protein (HR: 1.89; 95% CI: 1.32-2.71; P < 0.001). Similar analyses demonstrated an association with new-onset HF in males (HR: 1.77; 95% CI: 1.07-2.95; P = 0.028). In females, changes in gal-3 over time were neither associated with new-onset cancer nor new-onset HF. CONCLUSIONS: Gal-3, a marker of fibrosis, is associated with new-onset cancer and new-onset HF in males, but not in females.

U2 - 10.1016/j.jaccao.2023.03.015

DO - 10.1016/j.jaccao.2023.03.015

M3 - Article

C2 - 37614579

SN - 2666-0873

VL - 5

SP - 445

EP - 453

JO - Jacc: cardiooncology

JF - Jacc: cardiooncology

IS - 4

ER -

Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit